Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Hana Plonkova"'
Autor:
David Zihala, Tomas Jelinek, Tereza Sevcikova, Anjana Anilkumar Sithara, Veronika Kapustova, Daniel Bilek, Hana Sahinbegovic, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Ondrej Venglar, Jan Vrana, Vladimir Zidlik, Martin Havel, Zdenek Koristek, Matous Hrdinka, Zuzana Chyra, Michal Simicek, Roman Hajek
Publikováno v:
HemaSphere, Vol 7, p e003730a (2023)
Externí odkaz:
https://doaj.org/article/554b03b769da464b9aa0e4b59f091fed
Autor:
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukas Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar, Roman Hajek
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RR
Externí odkaz:
https://doaj.org/article/f4b149c2be57476793d1f90b53292d39
Autor:
Lucie Rihova, David Zihala, Michal Simicek, Tereza Sevcikova, Tomas Jelinek, Alexandra Jungova, Vladimir Maisnar, Veronika Kapustová, Roman Hájek, Lucie Broskevicova, Tereza Popkova, Ludek Pour, Petr Pavlicek, Ivan Spicka, Lenka Capkova, Hana Plonkova, Martin Stork, Renata Bezdekova, Jiri Minarik, Martin Havel, Vladimir Zidlik, Sabina Ševčíková, Jakub Radocha
Publikováno v:
Leukemia. 36:288-291
The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c642738d4faa696b2a7a51b91d9fb4ec
https://doi.org/10.1038/s41375-021-01343-w
https://doi.org/10.1038/s41375-021-01343-w
Autor:
Viera Sandecká, Lucie Rihova, Lenka Besse, Jiri Jarkovsky, Sabina Ševčíková, Ludek Pour, Veronika Kubaczková, Tomas Jelinek, Hana Plonkova, Lucie Brožová, Renata Bezdekova, Roman Hájek, Lenka Sedlarikova, David Vrabel, Martin Stork, Martina Almáši
Publikováno v:
European Journal of Haematology
Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea0ff7ab71c2c9a38f156508f824425
http://europepmc.org/articles/PMC7065130
http://europepmc.org/articles/PMC7065130
Autor:
Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Pospisilova, Petra Krhovska, Denisa Novakova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Vladimir Maisnar, Roman Hajek
Publikováno v:
Cancers; Volume 14; Issue 20; Pages: 5165
Background: We confirmed the benefit of addition of ixazomib to lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM) in unselected real-world population. We report the final analysis for overall survival (OS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c8927410f1f0face6bc5718e6852e39
https://doi.org/10.3390/cancers14205165
https://doi.org/10.3390/cancers14205165
Autor:
Juraj Duras, Roman Hájek, Michal Kaščák, Hana Plonkova, Katerina Benkova, Zdenek Koristek, Tereza Popkova, Michal Simicek, Lucie Cerna, Tomas Jelinek, Jana Mihalyova
Publikováno v:
Hematological oncology. 38(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81d101d9bbdc29975db153709f98e66
https://pubmed.ncbi.nlm.nih.gov/32323881
https://pubmed.ncbi.nlm.nih.gov/32323881
Autor:
Jaimal Kothari, Nadjoua Maouche, Maria Gavriatopoulou, Tomas Pika, Grant Vallance, Jiri Minarik, Efstathios Kastritis, Robin Aitchison, Hana Plonkova, Athanasios Zomas, Maria Kotsopoulou, Eirini Katodritou, Evangelos Terpos, Roman Hájek, Tomas Jelinek, Meletios A. Dimopoulos, Karthik Ramasamy, Matthew W Jenner, Ioannis Ntanasis-Stathopoulos
Publikováno v:
Annals of hematology. 99(5)
Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c725aaf35ba02383cb2614fcc6b8770
https://pubmed.ncbi.nlm.nih.gov/32236735
https://pubmed.ncbi.nlm.nih.gov/32236735
Autor:
Zdenek Koristek, Anjana Anilkumar Sithara, Lucie Broskevicova, Tereza Popkova, Martin Havel, Tereza Sevcikova, Veronika Kapustová, Roman Hájek, Vladimir Zidlik, Juli R. Bagó, Jan Vrana, Hana Plonkova, Hana Sahinbegovic, Tomas Jelinek, David Zihala, Michal Simicek
Publikováno v:
Blood. 138:2680-2680
I ntroduction Extramedullary disease (EMD) is a less frequent manifestation of multiple myeloma (MM), where MM plasma cells become independent of the bone marrow (BM) microenvironment and infiltrate other tissues and organs. The incidence of EMD is i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4283a09c7f0c4868ffb463b30b63d67
https://doi.org/10.1182/blood-2021-150876
https://doi.org/10.1182/blood-2021-150876
Autor:
Martin Stork, Jaroslav Bacovsky, Martin Mistrik, Hana Plonkova, Roman Hájek, Jakub Radocha, Tomas Jelinek, Ivan Spicka, Katerina Machalkova, Lenka Capkova, Alexandra Jungova, Jiri Minarik, Lubica Harvanova, Petr Pavlicek, Petra Krhovska, Pavel Jindra, Tomas Pika, Jan Straub, Vladimir Maisnar, Ludek Pour
Publikováno v:
Blood. 138:2716-2716
Background: The addition of ixazomib to the doublet lenalidomide and dexamethasone (RD) in relapsed and refractory multiple myeloma (RRMM) has shown significant benefit in progression free survival (PFS) in the TOURMALINE-MM1 study. Several real-worl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5195ab1220bb7a51d953be284f170b16
https://doi.org/10.1182/blood-2021-148836
https://doi.org/10.1182/blood-2021-148836
Publikováno v:
Blood. 136:6-7
Background: Evaluation of minimal residual disease (MRD) in multiple myeloma (MM) has become a standard procedure and has been incorporated to International Myeloma Working Group updated response criteria in 2016. Its value as an important prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f261831a3eba74c73556770f3581d52
https://doi.org/10.1182/blood-2020-142369
https://doi.org/10.1182/blood-2020-142369